Sign Out
There are no known clinically significant drug interactions but the effect of Epoetin may be potentiated by the simultaneous therapeutic administration of a haematinic agent such as ferrous sulphate when a deficiency state exists.
Since cyclosporine is bound by red blood cells there is potential for a drug interaction. If Epoetin is given concomitantly with cyclosporine, blood levels of cyclosporine should be monitored and the dose of cyclosporine adjusted as the haematocrit rises.
In patients with metastatic breast cancer, subcutaneous co-administration of 40,000 IU/mL epoetin alfa with transtuzumab (6mg/kg) had no effect on the pharmacokinetics of trastuzumab.
Continue with Google